Evidence map›Paper›PMID 41915226›Full record

ArticleImmunogenetics2026

Deciphering the genetic control of immune cell function at single-cell resolution: Disease-Specific Cis-eQTLs analysis of COVID-19.

E I Romanova, D I Tychinin, A M Shaymardanov, V E Akimov, A V Korobeinikova, V V Shiryagin, N I Guskova, V A Astafieva, A S Shingaliev, O A Antonova and 12 more

Abstract read
PubMed Publisher
In one paragraph

Article in Immunogenetics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

22 authors.

E I RomanovaFederal State Budgetary Institution "Centre for Strategic Planning and Management of Biomedical Health Risks" of the Federal Medical Biological Agency (Centre for Strategic Planning of FMBA of Russia), Pogodinskaya Street, 10, bld. 1, Moscow, 119121, Russia.
D I TychininFederal State Budgetary Institution "Centre for Strategic Planning and Management of Biomedical Health Risks" of the Federal Medical Biological Agency (Centre for Strategic Planning of FMBA of Russia), Pogodinskaya Street, 10, bld. 1, Moscow, 119121, Russia.
A M ShaymardanovFederal State Budgetary Institution "Centre for Strategic Planning and Management of Biomedical Health Risks" of the Federal Medical Biological Agency (Centre for Strategic Planning of FMBA of Russia), Pogodinskaya Street, 10, bld. 1, Moscow, 119121, Russia.
V E AkimovFederal State Budgetary Institution "Centre for Strategic Planning and Management of Biomedical Health Risks" of the Federal Medical Biological Agency (Centre for Strategic Planning of FMBA of Russia), Pogodinskaya Street, 10, bld. 1, Moscow, 119121, Russia.
A V KorobeinikovaFederal State Budgetary Institution "Centre for Strategic Planning and Management of Biomedical Health Risks" of the Federal Medical Biological Agency (Centre for Strategic Planning of FMBA of Russia), Pogodinskaya Street, 10, bld. 1, Moscow, 119121, Russia.
V V ShiryaginFederal State Budgetary Institution "Centre for Strategic Planning and Management of Biomedical Health Risks" of the Federal Medical Biological Agency (Centre for Strategic Planning of FMBA of Russia), Pogodinskaya Street, 10, bld. 1, Moscow, 119121, Russia.
N I GuskovaFederal State Budgetary Institution "Centre for Strategic Planning and Management of Biomedical Health Risks" of the Federal Medical Biological Agency (Centre for Strategic Planning of FMBA of Russia), Pogodinskaya Street, 10, bld. 1, Moscow, 119121, Russia.
V A AstafievaFederal State Budgetary Institution "Centre for Strategic Planning and Management of Biomedical Health Risks" of the Federal Medical Biological Agency (Centre for Strategic Planning of FMBA of Russia), Pogodinskaya Street, 10, bld. 1, Moscow, 119121, Russia.
A S ShingalievFederal State Budgetary Institution "Centre for Strategic Planning and Management of Biomedical Health Risks" of the Federal Medical Biological Agency (Centre for Strategic Planning of FMBA of Russia), Pogodinskaya Street, 10, bld. 1, Moscow, 119121, Russia.
O A AntonovaFederal State Budgetary Institution "Centre for Strategic Planning and Management of Biomedical Health Risks" of the Federal Medical Biological Agency (Centre for Strategic Planning of FMBA of Russia), Pogodinskaya Street, 10, bld. 1, Moscow, 119121, Russia.
L A GolubnikovaFederal State Budgetary Institution "Centre for Strategic Planning and Management of Biomedical Health Risks" of the Federal Medical Biological Agency (Centre for Strategic Planning of FMBA of Russia), Pogodinskaya Street, 10, bld. 1, Moscow, 119121, Russia.
S I MitrofanovFederal State Budgetary Institution "Centre for Strategic Planning and Management of Biomedical Health Risks" of the Federal Medical Biological Agency (Centre for Strategic Planning of FMBA of Russia), Pogodinskaya Street, 10, bld. 1, Moscow, 119121, Russia.
K S GrammatikatiFederal State Budgetary Institution "Centre for Strategic Planning and Management of Biomedical Health Risks" of the Federal Medical Biological Agency (Centre for Strategic Planning of FMBA of Russia), Pogodinskaya Street, 10, bld. 1, Moscow, 119121, Russia.
V S YudinFederal State Budgetary Institution "Centre for Strategic Planning and Management of Biomedical Health Risks" of the Federal Medical Biological Agency (Centre for Strategic Planning of FMBA of Russia), Pogodinskaya Street, 10, bld. 1, Moscow, 119121, Russia.
S M YudinFederal State Budgetary Institution "Centre for Strategic Planning and Management of Biomedical Health Risks" of the Federal Medical Biological Agency (Centre for Strategic Planning of FMBA of Russia), Pogodinskaya Street, 10, bld. 1, Moscow, 119121, Russia.
A V MakhotenkoFederal State Budgetary Institution "Centre for Strategic Planning and Management of Biomedical Health Risks" of the Federal Medical Biological Agency (Centre for Strategic Planning of FMBA of Russia), Pogodinskaya Street, 10, bld. 1, Moscow, 119121, Russia.
A A KeskinovFederal State Budgetary Institution "Centre for Strategic Planning and Management of Biomedical Health Risks" of the Federal Medical Biological Agency (Centre for Strategic Planning of FMBA of Russia), Pogodinskaya Street, 10, bld. 1, Moscow, 119121, Russia.
S A KraevoyFederal State Budgetary Institution "Centre for Strategic Planning and Management of Biomedical Health Risks" of the Federal Medical Biological Agency (Centre for Strategic Planning of FMBA of Russia), Pogodinskaya Street, 10, bld. 1, Moscow, 119121, Russia.
E A SnigirFederal State Budgetary Institution "Centre for Strategic Planning and Management of Biomedical Health Risks" of the Federal Medical Biological Agency (Centre for Strategic Planning of FMBA of Russia), Pogodinskaya Street, 10, bld. 1, Moscow, 119121, Russia.
P Yu VolchkovMoscow Center for Advanced Studies, Kulakova str. 20, Moscow, 123592, Russia.
D V SvetlichnyyFederal State Budgetary Institution "Centre for Strategic Planning and Management of Biomedical Health Risks" of the Federal Medical Biological Agency (Centre for Strategic Planning of FMBA of Russia), Pogodinskaya Street, 10, bld. 1, Moscow, 119121, Russia. dvsvetlichny@gmail.com.
V I SkvortsovaThe Federal Medical Biological Agency (FMBA of Russia), Volokolamskoye Shosse, bld. 30, Moscow, 123182, Russia.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Integrating whole-genome sequencing with single-cell RNA-seq data enhances the current understanding of how genomic differences across humans contribute to variations in gene activity. eQTL discovery offers a potent method for decoding genomic regulation and identifying population-specific genomic variants associated with gene expression differences. The current development of single-cell sequencing technologies provides a significant opportunity for precise and detailed profiling of both major and minor cell states, facilitating the identification of genomic variants and their effects within specific cellular contexts. Therefore, this study aims to investigate the combined analysis of paired whole-genome and single-cell RNA-seq data from 230,000 peripheral blood mononuclear cells (PBMCs) across 30 individuals. Overall, 1,233,644 cis-eQTLs were identified across 18 cell types in PBMCs. The results were thoroughly evaluated through conservation analysis, revealing that the most statistically significant eQTLs are associated with less conserved genomic regions and are concentrated in the regulatory areas of more divergent genes. Using deep learning-based cis-regulatory models, cis-eQTLs were further investigated to reveal the cell-type-specific context of variant activity. The analysis revealed how eQTLs influence the expression of key immune-related genes (NKG7, HLA, MIF, MS4A1), identifying transcription factors whose binding sites are disrupted by genomic variants. This study integrates genetics, single-cell transcriptomics, and deep learning models to reveal and understand the role of genomic variants in gene expression regulation.

Indexed as

COVID-19Leukocytes, MononuclearQuantitative Trait LociSARS-CoV-2Single-Cell AnalysisDeep LearningGene Expression RegulationHumansPolymorphism, Single NucleotideSingle-Cell Gene Expression AnalysisWhole Genome SequencingCOVID-19Deep learningeQTLSingle cellSNP

Identifiers

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.